Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Next Previous
Search
Trial Profile

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jan 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 13 Dec 2022 Results (n=7; By 31 March 2021) assessing safety and efficacy of Arm 3 of the PRISM platform study of acalabrutinib with magrolimab and rituximab in all molecular subtypes of relapsed/refractory diffuse large B-cell lymphoma, presented at the 64th American Society of Hematology Annual Meeting and Exposition.
  • 14 Dec 2021 Results (n=17) from treatment arm acalabrutinib with the anti-STAT3 allele-specific oligonucleotide AZD9150 , presented at the 63rd American Society of Hematology Annual Meeting and Exposition
  • 28 Apr 2021 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top